A small discovery about 16004-15-2

Although many compounds look similar to this compound(16004-15-2)Quality Control of 1-(Bromomethyl)-4-iodobenzene, numerous studies have shown that this compound(SMILES:IC1=CC=C(CBr)C=C1), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Journal of Enzyme Inhibition and Medicinal Chemistry called Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents, Author is Veschi, Serena; Carradori, Simone; De Lellis, Laura; Florio, Rosalba; Brocco, Davide; Secci, Daniela; Guglielmi, Paolo; Spano, Mattia; Sobolev, Anatoly P.; Cama, Alessandro, which mentions a compound: 16004-15-2, SMILESS is IC1=CC=C(CBr)C=C1, Molecular C7H6BrI, Quality Control of 1-(Bromomethyl)-4-iodobenzene.

Pancreatic cancer (PC) is one of the deadliest carcinomas and in most cases, which are diagnosed with locally advanced or metastatic disease, current therapeutic options are highly unsatisfactory. Based on the anti-proliferative effects shown by nitroxoline, an old urinary antibacterial agent, we explored a large library of newly synthesized derivatives to unravel the importance of the OH moiety and pyridine ring of the parent compound The new derivatives showed a valuable anti-proliferative effect and some displayed a greater effect as compared to nitroxoline against three pancreatic cancer cell lines with different genetic profiles. In particular, in silico pharmacokinetic data, clonogenicity assays and selectivity indexes of the most promising compounds showed several advantages for such derivatives, as compared to nitroxoline. Moreover, some of these novel compounds had stronger effects on cell viability and/or clonogenic capacity in PC cells as compared to erlotinib, a targeted agent approved for PC treatment.

Although many compounds look similar to this compound(16004-15-2)Quality Control of 1-(Bromomethyl)-4-iodobenzene, numerous studies have shown that this compound(SMILES:IC1=CC=C(CBr)C=C1), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics